Leading antihypertensive Diovan is in its class the obtain approval.

.. Leading antihypertensive Diovan is in its class the obtain approval, first-Novartis announced today that it successfully the EU Mutual Recognition Procedure evaluates completed in 14 countries for Diovan for the treatment and in the EU for the treatment of heart failure, the human after a heart attack treat of heart attacks. A proven, powerful remedy for high blood pressure is now listed as a potentially life-saving therapy for the more than 750,000 people in the EU, the risk of heart attack or other serious consequences, such as cardiovascular mortality, Hospitalization for heart failure, cardiac arrest with resuscitation or stroke.

This approval provides physicians with a proven life-saving treatment for these high-risk patients who have had heart attacks. Despite constant improvements, mortality remains high. Remains high. Now, Diovan the life of these high – high-risk patients after myocardial infarction extended beside them excellent antihypertensive effect. This indication is based on the VALIANT trial, andardial infarction.ival and fewer cardiovascular events in high risk patients after myocardial infarction.Underutilized nurseNurses the three groups felt fully utilized and has yet convince that they wear differently to patient care. The study indicates that many doctors felt at the new role of nurses is one unacceptable interference in their specialty the resistance of resistance of dividing professional responsibilities.

The authors of the study be Danielle D’Amour, a professor at the Universit? de Montr al Faculty of Nursing and the scientific director of Centre FERASI; Dominique Tremblay, a postdoctoral scholar ;? and Michelle Proulx, an R Profi with the Universit? en Montr? al FERASI Center. The study findings was based on data from three research projects.